Back

In vivo reprogramming of cytotoxic effector CD8+ T cells via fractalkine-conjugated mRNA-LNP

Corrigan, A. R.; Ngiow, S. F.; Statzu, M.; Pampena, M. B.; Nordin, J. M. L.; Albertus, A.; Carro, S. D.; Harper, J.; Stammen, R. L.; Wood, J. S. B.; Hamilton, J. T.; Ni, H.; Su, J.; Ramalingam, R.; Wu, V.; Paiardini, M.; Weissman, D.; Wherry, E. J.; Kreider, E.; Betts, M. R.

2025-10-30 immunology
10.1101/2025.10.29.685358 bioRxiv
Show abstract

Selective in vivo reprogramming of cytotoxic effector CD8+ T (Teff) cells holds tremendous promise as a therapeutic tool but has not yet been accomplished. Here, we demonstrate that fractalkine-conjugated mRNA lipid nanoparticles (mRNA-LNP) can specifically target and deliver mRNA to CX3CR1+ Teff cells in vitro and in vivo. In mice, fractalkine-conjugated LNP target up to 90% of blood and splenic Teff cells, and delivery of IL-2-encoding mRNA to Teff cells enables robust exogenous IL-2 secretion. In rhesus macaques, fractalkine-conjugated mRNA-LNP target up to [~]100% of peripheral blood Teff cells and delivery of CD62L-mRNA enables transient CD62L expression. Collectively, these data demonstrate the potential of natural receptor ligand-based targeting of mRNA-LNP for effective and efficient transient in vivo modification of Teff cells.

Published in Science Immunology (predicted rank #13) · training set

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.